ID   P85A_HUMAN              Reviewed;         724 AA.
AC   P27986; B3KT19; D3DWA0; E7EX19; Q15747; Q4VBZ7; Q53EM6; Q8IXA2;
AC   Q8N1C5;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   28-NOV-2006, sequence version 2.
DT   10-MAY-2017, entry version 211.
DE   RecName: Full=Phosphatidylinositol 3-kinase regulatory subunit alpha;
DE            Short=PI3-kinase regulatory subunit alpha;
DE            Short=PI3K regulatory subunit alpha;
DE            Short=PtdIns-3-kinase regulatory subunit alpha;
DE   AltName: Full=Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha;
DE            Short=PI3-kinase subunit p85-alpha;
DE            Short=PtdIns-3-kinase regulatory subunit p85-alpha;
GN   Name=PIK3R1; Synonyms=GRB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1849461; DOI=10.1016/0092-8674(91)90410-Z;
RA   Skolnik E.Y., Margolis B., Mohammadi M., Lowenstein E., Fischer R.,
RA   Drepps A., Ullrich A., Schlessinger J.;
RT   "Cloning of PI3 kinase-associated p85 utilizing a novel method for
RT   expression/cloning of target proteins for receptor tyrosine kinases.";
RL   Cell 65:83-90(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 4), INTERACTION WITH IRS1,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Skeletal muscle;
RX   PubMed=8628286; DOI=10.1128/MCB.16.5.2195;
RA   Antonetti D.A., Algenstaedt P., Kahn C.R.;
RT   "Insulin receptor substrate 1 binds two novel splice variants of the
RT   regulatory subunit of phosphatidylinositol 3-kinase in muscle and
RT   brain.";
RL   Mol. Cell. Biol. 16:2195-2203(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Skeletal muscle;
RA   Udelhoven M., Kotzka J., Knebel B., Klein E., Krone W.,
RA   Mueller-Wieland D.;
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   ILE-326.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   LYS-451.
RC   TISSUE=Placenta, and Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH PDGFRB.
RX   PubMed=7692233; DOI=10.1128/MCB.13.11.6889;
RA   Nishimura R., Li W., Kashishian A., Mondino A., Zhou M., Cooper J.,
RA   Schlessinger J.;
RT   "Two signaling molecules share a phosphotyrosine-containing binding
RT   site in the platelet-derived growth factor receptor.";
RL   Mol. Cell. Biol. 13:6889-6896(1993).
RN   [10]
RP   INTERACTION WITH INSR.
RX   PubMed=8276809;
RA   Van Horn D.J., Myers M.G. Jr., Backer J.M.;
RT   "Direct activation of the phosphatidylinositol 3'-kinase by the
RT   insulin receptor.";
RL   J. Biol. Chem. 269:29-32(1994).
RN   [11]
RP   FUNCTION IN FGFR4 SIGNALING.
RX   PubMed=7518429;
RA   Vainikka S., Joukov V., Wennstrom S., Bergman M., Pelicci P.G.,
RA   Alitalo K.;
RT   "Signal transduction by fibroblast growth factor receptor-4 (FGFR-4).
RT   Comparison with FGFR-1.";
RL   J. Biol. Chem. 269:18320-18326(1994).
RN   [12]
RP   INTERACTION WITH IGF1R.
RX   PubMed=7541045; DOI=10.1074/jbc.270.26.15639;
RA   Craparo A., O'Neill T.J., Gustafson T.A.;
RT   "Non-SH2 domains within insulin receptor substrate-1 and SHC mediate
RT   their phosphotyrosine-dependent interaction with the NPEY motif of the
RT   insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 270:15639-15643(1995).
RN   [13]
RP   INTERACTION WITH INSR.
RX   PubMed=7537849; DOI=10.1128/MCB.15.5.2500;
RA   Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J.;
RT   "Phosphotyrosine-dependent interaction of SHC and insulin receptor
RT   substrate 1 with the NPEY motif of the insulin receptor via a novel
RT   non-SH2 domain.";
RL   Mol. Cell. Biol. 15:2500-2508(1995).
RN   [14]
RP   INTERACTION WITH PDGFRA.
RX   PubMed=8940081; DOI=10.1074/jbc.271.48.30942;
RA   Yokote K., Margolis B., Heldin C.H., Claesson-Welsh L.;
RT   "Grb7 is a downstream signaling component of platelet-derived growth
RT   factor alpha- and beta-receptors.";
RL   J. Biol. Chem. 271:30942-30949(1996).
RN   [15]
RP   INTERACTION WITH KIT.
RX   PubMed=9038210; DOI=10.1074/jbc.272.9.5915;
RA   Price D.J., Rivnay B., Fu Y., Jiang S., Avraham S., Avraham H.;
RT   "Direct association of Csk homologous kinase (CHK) with the
RT   diphosphorylated site Tyr568/570 of the activated c-KIT in
RT   megakaryocytes.";
RL   J. Biol. Chem. 272:5915-5920(1997).
RN   [16]
RP   INTERACTION WITH AXL.
RX   PubMed=9178760; DOI=10.1038/sj.onc.1201123;
RA   Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R.,
RA   Ullrich A., Bartram C.R., Janssen J.W.;
RT   "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is
RT   mediated mainly by a multi-substrate docking-site.";
RL   Oncogene 14:2619-2631(1997).
RN   [17]
RP   INTERACTION WITH LAT.
RX   PubMed=9489702; DOI=10.1016/S0092-8674(00)80901-0;
RA   Zhang W., Sloan-Lancaster J., Kitchen J., Trible R.P., Samelson L.E.;
RT   "LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor
RT   to cellular activation.";
RL   Cell 92:83-92(1998).
RN   [18]
RP   INTERACTION WITH IRS4.
RX   PubMed=9553137; DOI=10.1074/jbc.273.17.10726;
RA   Fantin V.R., Sparling J.D., Slot J.W., Keller S.R., Lienhard G.E.,
RA   Lavan B.E.;
RT   "Characterization of insulin receptor substrate 4 in human embryonic
RT   kidney 293 cells.";
RL   J. Biol. Chem. 273:10726-10732(1998).
RN   [19]
RP   INTERACTION WITH TRAT1.
RX   PubMed=9687533; DOI=10.1084/jem.188.3.561;
RA   Bruyns E., Marie-Cardine A., Kirchgessner H., Sagolla K.,
RA   Shevchenko A., Mann M., Autschbach F., Bensussan A., Meuer S.,
RA   Schraven B.;
RT   "T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-
RT   linked dimer associated with the TCR-CD3-zeta complex, recruits
RT   intracellular signaling proteins to the plasma membrane.";
RL   J. Exp. Med. 188:561-575(1998).
RN   [20]
RP   INTERACTION WITH HCST.
RX   PubMed=10528161;
RA   Chang C., Dietrich J., Harpur A.G., Lindquist J.A., Haude A.,
RA   Loke Y.W., King A., Colonna M., Trowsdale J., Wilson M.J.;
RT   "KAP10, a novel transmembrane adapter protein genetically linked to
RT   DAP12 but with unique signaling properties.";
RL   J. Immunol. 163:4651-4654(1999).
RN   [21]
RP   INTERACTION WITH CBLB.
RX   PubMed=10086340; DOI=10.1038/sj.onc.1202499;
RA   Ettenberg S.A., Keane M.M., Nau M.M., Frankel M., Wang L.-M.,
RA   Pierce J.H., Lipkowitz S.;
RT   "cbl-b inhibits epidermal growth factor receptor signaling.";
RL   Oncogene 18:1855-1866(1999).
RN   [22]
RP   INTERACTION WITH FGR AND HCK.
RX   PubMed=10739672; DOI=10.1006/excr.2000.4816;
RA   Axelsson L., Hellberg C., Melander F., Smith D., Zheng L.,
RA   Andersson T.;
RT   "Clustering of beta(2)-integrins on human neutrophils activates dual
RT   signaling pathways to PtdIns 3-kinase.";
RL   Exp. Cell Res. 256:257-263(2000).
RN   [23]
RP   INTERACTION WITH ERBB4.
RX   PubMed=10867024; DOI=10.1074/jbc.C901015199;
RA   Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C.,
RA   Carraway K.L. III;
RT   "Ligand discrimination in signaling through an ErbB4 receptor
RT   homodimer.";
RL   J. Biol. Chem. 275:19803-19807(2000).
RN   [24]
RP   INTERACTION WITH CBLB, AND UBIQUITINATION.
RX   PubMed=11087752; DOI=10.1074/jbc.M008901200;
RA   Fang D., Wang H.-Y., Fang N., Altman Y., Elly C., Liu Y.-C.;
RT   "Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol
RT   3-kinase for ubiquitination in T cells.";
RL   J. Biol. Chem. 276:4872-4878(2001).
RN   [25]
RP   INTERACTION WITH CD3Z AND CD28, AND UBIQUITINATION.
RX   PubMed=11526404; DOI=10.1038/ni0901-870;
RA   Fang D., Liu Y.-C.;
RT   "Proteolysis-independent regulation of PI3K by Cbl-b-mediated
RT   ubiquitination in T cells.";
RL   Nat. Immunol. 2:870-875(2001).
RN   [26]
RP   INTERACTION WITH NISCH.
RX   PubMed=11912194; DOI=10.1074/jbc.M111838200;
RA   Sano H., Liu S.C.H., Lane W.S., Piletz J.E., Lienhard G.E.;
RT   "Insulin receptor substrate 4 associates with the protein IRAS.";
RL   J. Biol. Chem. 277:19439-19447(2002).
RN   [27]
RP   INTERACTION WITH LAX1.
RX   PubMed=12359715; DOI=10.1074/jbc.M208946200;
RA   Zhu M., Janssen E., Leung K., Zhang W.;
RT   "Molecular cloning of a novel gene encoding a membrane-associated
RT   adaptor protein (LAX) in lymphocyte signaling.";
RL   J. Biol. Chem. 277:46151-46158(2002).
RN   [28]
RP   INTERACTION WITH HIV-1 NEF.
RX   PubMed=12009866; DOI=10.1006/viro.2002.1365;
RA   Linnemann T., Zheng Y.-H., Mandic R., Peterlin B.M.;
RT   "Interaction between Nef and phosphatidylinositol-3-kinase leads to
RT   activation of p21-activated kinase and increased production of HIV.";
RL   Virology 294:246-255(2002).
RN   [29]
RP   INTERACTION WITH HCV NS5A.
RX   PubMed=12186904; DOI=10.1128/JVI.76.18.9207-9217.2002;
RA   He Y., Nakao H., Tan S.-L., Polyak S.J., Neddermann P., Vijaysri S.,
RA   Jacobs B.L., Katze M.G.;
RT   "Subversion of cell signaling pathways by hepatitis C virus
RT   nonstructural 5A protein via interaction with Grb2 and P85
RT   phosphatidylinositol 3-kinase.";
RL   J. Virol. 76:9207-9217(2002).
RN   [30]
RP   INTERACTION WITH NTRK1.
RX   PubMed=15488758; DOI=10.1016/j.ccr.2004.09.011;
RA   Tacconelli A., Farina A.R., Cappabianca L., Desantis G., Tessitore A.,
RA   Vetuschi A., Sferra R., Rucci N., Argenti B., Screpanti I., Gulino A.,
RA   Mackay A.R.;
RT   "TrkA alternative splicing: a regulated tumor-promoting switch in
RT   human neuroblastoma.";
RL   Cancer Cell 6:347-360(2004).
RN   [31]
RP   REVIEW ON INTERACTION WITH KIT AND ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [32]
RP   INTERACTION WITH BCR.
RX   PubMed=15302586; DOI=10.1016/j.yexcr.2004.05.010;
RA   Laurent C.E., Smithgall T.E.;
RT   "The c-Fes tyrosine kinase cooperates with the breakpoint cluster
RT   region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-
RT   dependent manner.";
RL   Exp. Cell Res. 299:188-198(2004).
RN   [33]
RP   PHOSPHORYLATION BY FGR.
RX   PubMed=15561106; DOI=10.1016/j.yexcr.2004.09.005;
RA   Continolo S., Baruzzi A., Majeed M., Caveggion E., Fumagalli L.,
RA   Lowell C.A., Berton G.;
RT   "The proto-oncogene Fgr regulates cell migration and this requires its
RT   plasma membrane localization.";
RL   Exp. Cell Res. 302:253-269(2005).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [35]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPRJ.
RX   PubMed=18348712; DOI=10.1042/BJ20071317;
RA   Tsuboi N., Utsunomiya T., Roberts R.L., Ito H., Takahashi K., Noda M.,
RA   Takahashi T.;
RT   "The tyrosine phosphatase CD148 interacts with the p85 regulatory
RT   subunit of phosphoinositide 3-kinase.";
RL   Biochem. J. 413:193-200(2008).
RN   [36]
RP   INTERACTION WITH ERBB4.
RX   PubMed=18721752; DOI=10.1016/j.chembiol.2008.07.006;
RA   Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J.,
RA   MacBeath G.;
RT   "System-wide investigation of ErbB4 reveals 19 sites of Tyr
RT   phosphorylation that are unusually selective in their recruitment
RT   properties.";
RL   Chem. Biol. 15:808-817(2008).
RN   [37]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL
RT   (CD178) by phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [38]
RP   INTERACTION WITH FGFR3.
RX   PubMed=19286672; DOI=10.1093/hmg/ddp116;
RA   Salazar L., Kashiwada T., Krejci P., Muchowski P., Donoghue D.,
RA   Wilcox W.R., Thompson L.M.;
RT   "A novel interaction between fibroblast growth factor receptor 3 and
RT   the p85 subunit of phosphoinositide 3-kinase: activation-dependent
RT   regulation of ERK by p85 in multiple myeloma cells.";
RL   Hum. Mol. Genet. 18:1951-1961(2009).
RN   [39]
RP   REVIEW ON ROLE IN FGFR1 SIGNALING.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-580, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [41]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [42]
RP   FUNCTION, AND INTERACTION WITH XBP1.
RX   PubMed=20348923; DOI=10.1038/nm.2121;
RA   Winnay J.N., Boucher J., Mori M.A., Ueki K., Kahn C.R.;
RT   "A regulatory subunit of phosphoinositide 3-kinase increases the
RT   nuclear accumulation of X-box-binding protein-1 to modulate the
RT   unfolded protein response.";
RL   Nat. Med. 16:438-445(2010).
RN   [43]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 UL46.
RX   PubMed=21228233; DOI=10.1128/JVI.01877-10;
RA   Wagner M.J., Smiley J.R.;
RT   "Herpes simplex virus requires VP11/12 to activate Src family kinase-
RT   phosphoinositide 3-kinase-Akt signaling.";
RL   J. Virol. 85:2803-2812(2011).
RN   [44]
RP   INVOLVEMENT IN AGM7.
RX   PubMed=22351933; DOI=10.1084/jem.20112533;
RA   Conley M.E., Dobbs A.K., Quintana A.M., Bosompem A., Wang Y.D.,
RA   Coustan-Smith E., Smith A.M., Perez E.E., Murray P.J.;
RT   "Agammaglobulinemia and absent B lineage cells in a patient lacking
RT   the p85? subunit of PI3K.";
RL   J. Exp. Med. 209:463-470(2012).
RN   [45]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [46]
RP   INVOLVEMENT IN SHORTS, AND VARIANT SHORTS TRP-649.
RX   PubMed=23810382; DOI=10.1016/j.ajhg.2013.06.005;
RG   FORGE Canada Consortium;
RA   Dyment D.A., Smith A.C., Alcantara D., Schwartzentruber J.A.,
RA   Basel-Vanagaite L., Curry C.J., Temple I.K., Reardon W., Mansour S.,
RA   Haq M.R., Gilbert R., Lehmann O.J., Vanstone M.R., Beaulieu C.L.,
RA   Majewski J., Bulman D.E., O'Driscoll M., Boycott K.M., Innes A.M.,
RA   Friedman J., Michaud J., Bernier F., Brudno M., Fernandez B.,
RA   Knoppers B., Samuels M., Scherer S.;
RT   "Mutations in PIK3R1 cause SHORT syndrome.";
RL   Am. J. Hum. Genet. 93:158-166(2013).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-154 AND SER-279, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [48]
RP   INTERACTION WITH VARICELLA VIRUS ORF12.
RX   PubMed=23192871; DOI=10.1128/JVI.02395-12;
RA   Liu X., Cohen J.I.;
RT   "Varicella-zoster virus ORF12 protein activates the
RT   phosphatidylinositol 3-kinase/Akt pathway to regulate cell cycle
RT   progression.";
RL   J. Virol. 87:1842-1848(2013).
RN   [49]
RP   INTERACTION WITH FAM83B.
RX   PubMed=23676467;
RA   Cipriano R., Miskimen K.L., Bryson B.L., Foy C.R., Bartel C.A.,
RA   Jackson M.W.;
RT   "FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates
RT   to promote epithelial cell transformation and resistance to targeted
RT   therapies.";
RL   Oncotarget 4:729-738(2013).
RN   [50]
RP   INVOLVEMENT IN IMD36.
RX   PubMed=25133428; DOI=10.1172/JCI75746;
RA   Deau M.C., Heurtier L., Frange P., Suarez F., Bole-Feysot C.,
RA   Nitschke P., Cavazzana M., Picard C., Durandy A., Fischer A.,
RA   Kracker S.;
RT   "A human immunodeficiency caused by mutations in the PIK3R1 gene.";
RL   J. Clin. Invest. 124:3923-3928(2014).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-85.
RX   PubMed=8648629; DOI=10.1006/jmbi.1996.0190;
RA   Liang J., Chen J.K., Schreiber S.L., Clardy J.;
RT   "Crystal structure of P13K SH3 domain at 2.0-A resolution.";
RL   J. Mol. Biol. 257:632-643(1996).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 324-434.
RX   PubMed=8599763; DOI=10.1038/nsb0496-364;
RA   Nolte R.T., Eck M.J., Schlessinger J., Shoelson S.E., Harrison S.C.;
RT   "Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain
RT   and its phosphopeptide complexes.";
RL   Nat. Struct. Biol. 3:364-373(1996).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 115-298.
RX   PubMed=8962058; DOI=10.1073/pnas.93.25.14373;
RA   Musacchio A., Cantley L.C., Harrison S.C.;
RT   "Crystal structure of the breakpoint cluster region-homology domain
RT   from phosphoinositide 3-kinase p85 alpha subunit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:14373-14378(1996).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 617-724 IN COMPLEX WITH
RP   PDGFRB.
RX   PubMed=11567151; DOI=10.1107/S0907444901012434;
RA   Pauptit R.A., Dennis C.A., Derbyshire D.J., Breeze A.L., Weston S.A.,
RA   Rowsell S., Murshudov G.N.;
RT   "NMR trial models: experiences with the colicin immunity protein Im7
RT   and the p85alpha C-terminal SH2-peptide complex.";
RL   Acta Crystallogr. D 57:1397-1404(2001).
RN   [56]
RP   STRUCTURE BY NMR OF 1-79.
RX   PubMed=7681364; DOI=10.1016/0092-8674(93)90582-B;
RA   Koyama S., Yu H., Dalgarno D.C., Shin T.B., Zydowsky L.D.,
RA   Schreiber S.L.;
RT   "Structure of the PI3K SH3 domain and analysis of the SH3 family.";
RL   Cell 72:945-952(1993).
RN   [57]
RP   STRUCTURE BY NMR OF 91-104.
RX   PubMed=8961927; DOI=10.1021/bi9620969;
RA   Renzoni D.A., Pugh D.J., Siligardi G., Das P., Morton C.J., Rossi C.,
RA   Waterfield M.D., Campbell I.D., Ladbury J.E.;
RT   "Structural and thermodynamic characterization of the interaction of
RT   the SH3 domain from Fyn with the proline-rich binding site on the p85
RT   subunit of PI3-kinase.";
RL   Biochemistry 35:15646-15653(1996).
RN   [58]
RP   STRUCTURE BY NMR OF 617-724.
RX   PubMed=8670861;
RA   Breeze A.L., Kara B.V., Barratt D.G., Anderson M., Smith J.C.,
RA   Luke R.W., Best J.R., Cartlidge S.A.;
RT   "Structure of a specific peptide complex of the carboxy-terminal SH2
RT   domain from the p85 alpha subunit of phosphatidylinositol 3-kinase.";
RL   EMBO J. 15:3579-3589(1996).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 431-600, AND FUNCTION.
RX   PubMed=17626883; DOI=10.1126/science.1135394;
RA   Miled N., Yan Y., Hon W.C., Perisic O., Zvelebil M., Inbar Y.,
RA   Schneidman-Duhovny D., Wolfson H.J., Backer J.M., Williams R.L.;
RT   "Mechanism of two classes of cancer mutations in the phosphoinositide
RT   3-kinase catalytic subunit.";
RL   Science 317:239-242(2007).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (3.05 ANGSTROMS) OF 322-600.
RX   PubMed=18079394; DOI=10.1126/science.1150799;
RA   Huang C.-H., Mandelker D., Schmidt-Kittler O., Samuels Y.,
RA   Velculescu V.E., Kinzler K.W., Vogelstein B., Gabelli S.B.,
RA   Amzel L.M.;
RT   "The structure of a human p110alpha/p85alpha complex elucidates the
RT   effects of oncogenic PI3Kalpha mutations.";
RL   Science 318:1744-1748(2007).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 322-694, FUNCTION, AND
RP   SUBUNIT.
RX   PubMed=19805105; DOI=10.1073/pnas.0908444106;
RA   Mandelker D., Gabelli S.B., Schmidt-Kittler O., Zhu J., Cheong I.,
RA   Huang C.H., Kinzler K.W., Vogelstein B., Amzel L.M.;
RT   "A frequent kinase domain mutation that changes the interaction
RT   between PI3Kalpha and the membrane.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:16996-17001(2009).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1-83.
RX   PubMed=19919182; DOI=10.1515/BC.2010.003;
RA   Batra-Safferling R., Granzin J., Modder S., Hoffmann S., Willbold D.;
RT   "Structural studies of the phosphatidylinositol 3-kinase (PI3K) SH3
RT   domain in complex with a peptide ligand: role of the anchor residue in
RT   ligand binding.";
RL   Biol. Chem. 391:33-42(2010).
RN   [63]
RP   VARIANT ILE-326.
RX   PubMed=9032108; DOI=10.2337/diab.46.3.494;
RA   Hansen T., Andersen C.B., Echwald S.M., Urhammer S.A., Clausen J.O.,
RA   Vestergaard H., Owens D., Hansen L., Pedersen O.;
RT   "Identification of a common amino acid polymorphism in the p85alpha
RT   regulatory subunit of phosphatidylinositol 3-kinase: effects on
RT   glucose disappearance constant, glucose effectiveness, and the insulin
RT   sensitivity index.";
RL   Diabetes 46:494-501(1997).
RN   [64]
RP   VARIANTS ILE-326 AND GLN-409, AND CHARACTERIZATION OF VARIANTS ILE-326
RP   AND GLN-409.
RX   PubMed=10768093; DOI=10.1007/s001250050050;
RA   Baynes K.C.R., Beeton C.A., Panayotou G., Stein R., Soos M.,
RA   Hansen T., Simpson H., O'Rahilly S., Shepherd P.R., Whitehead J.P.;
RT   "Natural variants of human p85 alpha phosphoinositide 3-kinase in
RT   severe insulin resistance: a novel variant with impaired insulin-
RT   stimulated lipid kinase activity.";
RL   Diabetologia 43:321-331(2000).
RN   [65]
RP   VARIANTS SHORTS LYS-489 AND ILE-539 DEL.
RX   PubMed=23810378; DOI=10.1016/j.ajhg.2013.05.019;
RA   Thauvin-Robinet C., Auclair M., Duplomb L., Caron-Debarle M.,
RA   Avila M., St-Onge J., Le Merrer M., Le Luyer B., Heron D.,
RA   Mathieu-Dramard M., Bitoun P., Petit J.M., Odent S., Amiel J.,
RA   Picot D., Carmignac V., Thevenon J., Callier P., Laville M.,
RA   Reznik Y., Fagour C., Nunes M.L., Capeau J., Lascols O., Huet F.,
RA   Faivre L., Vigouroux C., Riviere J.B.;
RT   "PIK3R1 mutations cause syndromic insulin resistance with
RT   lipoatrophy.";
RL   Am. J. Hum. Genet. 93:141-149(2013).
RN   [66]
RP   VARIANT SHORTS TRP-649.
RX   PubMed=23810379; DOI=10.1016/j.ajhg.2013.05.023;
RA   Chudasama K.K., Winnay J., Johansson S., Claudi T., Konig R.,
RA   Haldorsen I., Johansson B., Woo J.R., Aarskog D., Sagen J.V.,
RA   Kahn C.R., Molven A., Njolstad P.R.;
RT   "SHORT syndrome with partial lipodystrophy due to impaired
RT   phosphatidylinositol 3 kinase signaling.";
RL   Am. J. Hum. Genet. 93:150-157(2013).
CC   -!- FUNCTION: Binds to activated (phosphorylated) protein-Tyr kinases,
CC       through its SH2 domain, and acts as an adapter, mediating the
CC       association of the p110 catalytic unit to the plasma membrane.
CC       Necessary for the insulin-stimulated increase in glucose uptake
CC       and glycogen synthesis in insulin-sensitive tissues. Plays an
CC       important role in signaling in response to FGFR1, FGFR2, FGFR3,
CC       FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role
CC       in ITGB2 signaling (PubMed:17626883, PubMed:19805105,
CC       PubMed:7518429). Modulates the cellular response to ER stress by
CC       promoting nuclear translocation of XBP1 isoform 2 in a ER stress-
CC       and/or insulin-dependent manner during metabolic overloading in
CC       the liver and hence plays a role in glucose tolerance improvement
CC       (PubMed:20348923). {ECO:0000269|PubMed:17626883,
CC       ECO:0000269|PubMed:19805105, ECO:0000269|PubMed:20348923,
CC       ECO:0000269|PubMed:7518429}.
CC   -!- SUBUNIT: Interacts (via SH2 domain) with CSF1R (tyrosine
CC       phosphorylated). Interacts with PIK3R2; the interaction is
CC       dissociated in an insulin-dependent manner (By similarity).
CC       Interacts with XBP1 isoform 2; the interaction is direct and
CC       induces translocation of XBP1 isoform 2 into the nucleus in a ER
CC       stress- and/or insulin-dependent but PI3K-independent manner
CC       (PubMed:20348923). Heterodimer of a regulatory subunit PIK3R1 and
CC       a p110 catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts
CC       with FER. Interacts (via SH2 domain) with TEK/TIE2 (tyrosine
CC       phosphorylated). Interacts with PTK2/FAK1 (By similarity).
CC       Interacts with phosphorylated TOM1L1. Interacts with
CC       phosphorylated LIME1 upon TCR and/or BCR activation. Interacts
CC       with SOCS7. Interacts with RUFY3. Interacts (via SH2 domain) with
CC       CSF1R (tyrosine phosphorylated). Interacts with LYN (via SH3
CC       domain); this enhances enzyme activity (By similarity). Interacts
CC       with phosphorylated LAT, LAX1 and TRAT1 upon TCR activation.
CC       Interacts with CBLB. Interacts with HIV-1 Nef to activate the Nef
CC       associated p21-activated kinase (PAK). This interaction depends on
CC       the C-terminus of both proteins and leads to increased production
CC       of HIV. Interacts with HCV NS5A. The SH2 domains interact with the
CC       YTHM motif of phosphorylated INSR in vitro. Also interacts with
CC       tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and
CC       CD3Z upon T-cell activation. Interacts with IRS1 and
CC       phosphorylated IRS4, as well as with NISCH and HCST. Interacts
CC       with FASLG, KIT and BCR. Interacts with AXL, FGFR1, FGFR2, FGFR3
CC       and FGFR4 (phosphorylated). Interacts with FGR and HCK. Interacts
CC       with PDGFRA (tyrosine phosphorylated) and PDGFRB (tyrosine
CC       phosphorylated). Interacts with ERBB4 (phosphorylated). Interacts
CC       with NTRK1 (phosphorylated upon ligand-binding). Interacts with
CC       herpes simplex virus 1 UL46 and varicella virus ORF12; these
CC       interactions activate the PI3K/AKT pathway. Interacts with FAM83B;
CC       activates the PI3K/AKT signaling cascade (PubMed:23676467).
CC       {ECO:0000250|UniProtKB:P23727, ECO:0000250|UniProtKB:P26450,
CC       ECO:0000250|UniProtKB:Q63787, ECO:0000269|PubMed:10086340,
CC       ECO:0000269|PubMed:10528161, ECO:0000269|PubMed:10739672,
CC       ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:11087752,
CC       ECO:0000269|PubMed:11526404, ECO:0000269|PubMed:11567151,
CC       ECO:0000269|PubMed:11912194, ECO:0000269|PubMed:12009866,
CC       ECO:0000269|PubMed:12186904, ECO:0000269|PubMed:12359715,
CC       ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:19286672,
CC       ECO:0000269|PubMed:19805105, ECO:0000269|PubMed:19807924,
CC       ECO:0000269|PubMed:20348923, ECO:0000269|PubMed:21228233,
CC       ECO:0000269|PubMed:23676467, ECO:0000269|PubMed:7537849,
CC       ECO:0000269|PubMed:7541045, ECO:0000269|PubMed:7692233,
CC       ECO:0000269|PubMed:8276809, ECO:0000269|PubMed:8628286,
CC       ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:9038210,
CC       ECO:0000269|PubMed:9178760, ECO:0000269|PubMed:9489702,
CC       ECO:0000269|PubMed:9553137, ECO:0000269|PubMed:9687533}.
CC   -!- INTERACTION:
CC       Q8IZP0:ABI1; NbExp=8; IntAct=EBI-79464, EBI-375446;
CC       P42684:ABL2; NbExp=2; IntAct=EBI-79464, EBI-1102694;
CC       P10275:AR; NbExp=5; IntAct=EBI-79464, EBI-608057;
CC       P22681:CBL; NbExp=5; IntAct=EBI-79464, EBI-518228;
CC       P10747:CD28; NbExp=8; IntAct=EBI-79464, EBI-4314301;
CC       Q13111:CHAF1A; NbExp=2; IntAct=EBI-79464, EBI-1020839;
CC       Q8IY22:CMIP; NbExp=2; IntAct=EBI-79464, EBI-7689652;
CC       P46108:CRK; NbExp=2; IntAct=EBI-79464, EBI-886;
CC       P46109:CRKL; NbExp=2; IntAct=EBI-79464, EBI-910;
CC       P16410:CTLA4; NbExp=3; IntAct=EBI-79464, EBI-1030991;
CC       Q9Y2H0:DLGAP4; NbExp=2; IntAct=EBI-79464, EBI-722139;
CC       P00533:EGFR; NbExp=5; IntAct=EBI-79464, EBI-297353;
CC       P41970:ELK3; NbExp=2; IntAct=EBI-79464, EBI-1758534;
CC       P04626:ERBB2; NbExp=11; IntAct=EBI-79464, EBI-641062;
CC       P21860:ERBB3; NbExp=40; IntAct=EBI-79464, EBI-720706;
CC       P03372:ESR1; NbExp=6; IntAct=EBI-79464, EBI-78473;
CC       P48023:FASLG; NbExp=2; IntAct=EBI-79464, EBI-495538;
CC       P11362:FGFR1; NbExp=5; IntAct=EBI-79464, EBI-1028277;
CC       P17948:FLT1; NbExp=2; IntAct=EBI-79464, EBI-1026718;
CC       P36888:FLT3; NbExp=2; IntAct=EBI-79464, EBI-3946257;
CC       Q13480:GAB1; NbExp=33; IntAct=EBI-79464, EBI-517684;
CC       P62993:GRB2; NbExp=4; IntAct=EBI-79464, EBI-401755;
CC       P42858:HTT; NbExp=7; IntAct=EBI-79464, EBI-466029;
CC       P08069:IGF1R; NbExp=4; IntAct=EBI-79464, EBI-475981;
CC       P06213:INSR; NbExp=3; IntAct=EBI-79464, EBI-475899;
CC       P35568:IRS1; NbExp=12; IntAct=EBI-79464, EBI-517592;
CC       P35570:Irs1 (xeno); NbExp=2; IntAct=EBI-79464, EBI-520230;
CC       Q9Y4H2:IRS2; NbExp=3; IntAct=EBI-79464, EBI-1049582;
CC       P10721:KIT; NbExp=19; IntAct=EBI-79464, EBI-1379503;
CC       Q86VI4-3:LAPTM4B; NbExp=2; IntAct=EBI-79464, EBI-3267286;
CC       O43561:LAT; NbExp=4; IntAct=EBI-79464, EBI-1222766;
CC       Q92918:MAP4K1; NbExp=2; IntAct=EBI-79464, EBI-881;
CC       P45983:MAPK8; NbExp=6; IntAct=EBI-79464, EBI-286483;
CC       P08581:MET; NbExp=6; IntAct=EBI-79464, EBI-1039152;
CC       Q8WX92:NELFB; NbExp=2; IntAct=EBI-79464, EBI-347721;
CC       P03496:NS (xeno); NbExp=6; IntAct=EBI-79464, EBI-2547442;
CC       Q6PFX7:Nyap1 (xeno); NbExp=4; IntAct=EBI-79464, EBI-7447489;
CC       Q8BM65-4:Nyap2 (xeno); NbExp=3; IntAct=EBI-79464, EBI-7447598;
CC       P09619:PDGFRB; NbExp=19; IntAct=EBI-79464, EBI-641237;
CC       P42336:PIK3CA; NbExp=14; IntAct=EBI-79464, EBI-2116585;
CC       P42338:PIK3CB; NbExp=3; IntAct=EBI-9090282, EBI-2609540;
CC       P16885:PLCG2; NbExp=2; IntAct=EBI-79464, EBI-617403;
CC       P49023:PXN; NbExp=2; IntAct=EBI-79464, EBI-702209;
CC       Q13905:RAPGEF1; NbExp=2; IntAct=EBI-79464, EBI-976876;
CC       P26373:RPL13; NbExp=2; IntAct=EBI-79464, EBI-356849;
CC       P19793:RXRA; NbExp=8; IntAct=EBI-79464, EBI-78598;
CC       Q9NP31:SH2D2A; NbExp=3; IntAct=EBI-9090282, EBI-490630;
CC       Q9UPX8:SHANK2; NbExp=2; IntAct=EBI-79464, EBI-1570571;
CC       P29353:SHC1; NbExp=3; IntAct=EBI-79464, EBI-78835;
CC       Q9H0K1:SIK2; NbExp=7; IntAct=EBI-79464, EBI-1181664;
CC       Q96EB6:SIRT1; NbExp=3; IntAct=EBI-79464, EBI-1802965;
CC       Q07889:SOS1; NbExp=3; IntAct=EBI-79464, EBI-297487;
CC       P12931:SRC; NbExp=6; IntAct=EBI-79464, EBI-621482;
CC       P30874:SSTR2; NbExp=5; IntAct=EBI-79464, EBI-6266898;
CC       P58753:TIRAP; NbExp=3; IntAct=EBI-79464, EBI-528644;
CC       O15455:TLR3; NbExp=2; IntAct=EBI-79464, EBI-6116630;
CC       Q15661:TPSAB1; NbExp=2; IntAct=EBI-79464, EBI-1761369;
CC       Q9ULW0:TPX2; NbExp=2; IntAct=EBI-79464, EBI-1037322;
CC       Q9UKW4:VAV3; NbExp=2; IntAct=EBI-79464, EBI-297568;
CC       Q99152:VP3 (xeno); NbExp=3; IntAct=EBI-79464, EBI-1776808;
CC       Q8IUH5:ZDHHC17; NbExp=2; IntAct=EBI-9090282, EBI-524753;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=P27986-1; Sequence=Displayed;
CC       Name=2; Synonyms=AS53;
CC         IsoId=P27986-2; Sequence=VSP_021842, VSP_021843;
CC       Name=3; Synonyms=p46;
CC         IsoId=P27986-3; Sequence=VSP_021841, VSP_021844;
CC       Name=4; Synonyms=p85I;
CC         IsoId=P27986-4; Sequence=VSP_021845;
CC       Name=5;
CC         IsoId=P27986-5; Sequence=VSP_045903;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Isoform 2 is expressed in skeletal muscle and
CC       brain, and at lower levels in kidney and cardiac muscle. Isoform 2
CC       and isoform 4 are present in skeletal muscle (at protein level).
CC       {ECO:0000269|PubMed:8628286}.
CC   -!- DOMAIN: The SH3 domain mediates the binding to CBLB, and to HIV-1
CC       Nef.
CC   -!- PTM: Polyubiquitinated in T-cells by CBLB; which does not promote
CC       proteasomal degradation but impairs association with CD28 and CD3Z
CC       upon T-cell activation. {ECO:0000269|PubMed:11087752,
CC       ECO:0000269|PubMed:11526404}.
CC   -!- PTM: Phosphorylated. Tyrosine phosphorylated in response to
CC       signaling by FGFR1, FGFR2, FGFR3 and FGFR4. Phosphorylated by
CC       CSF1R. Phosphorylated by ERBB4. Phosphorylated on tyrosine
CC       residues by TEK/TIE2. Dephosphorylated by PTPRJ. Phosphorylated by
CC       PIK3CA at Ser-608; phosphorylation is stimulated by insulin and
CC       PDGF. The relevance of phosphorylation by PIK3CA is however
CC       unclear (By similarity). Phosphorylated in response to KIT and
CC       KITLG/SCF. Phosphorylated by FGR. {ECO:0000250,
CC       ECO:0000269|PubMed:15561106, ECO:0000269|PubMed:18348712}.
CC   -!- DISEASE: Agammaglobulinemia 7, autosomal recessive (AGM7)
CC       [MIM:615214]: A primary immunodeficiency characterized by
CC       profoundly low or absent serum antibodies and low or absent
CC       circulating B-cells due to an early block of B-cell development.
CC       Affected individuals develop severe infections in the first years
CC       of life. {ECO:0000269|PubMed:22351933}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: SHORT syndrome (SHORTS) [MIM:269880]: A rare, multisystem
CC       disease characterized by short stature, anomalies of the anterior
CC       chamber of the eye, characteristic facial features such as
CC       triangular facies, lack of facial fat, and hypoplastic nasal alae
CC       with overhanging columella, partial lipodystrophy, hernias,
CC       hyperextensibility, and delayed dentition. The clinical phenotype
CC       can include insulin resistance, nephrocalcinosis, and hearing
CC       deficits. Developmental milestones and cognition are normal.
CC       {ECO:0000269|PubMed:23810378, ECO:0000269|PubMed:23810379,
CC       ECO:0000269|PubMed:23810382}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Immunodeficiency 36 (IMD36) [MIM:616005]: A primary
CC       immunodeficiency characterized by impaired B-cell function,
CC       hypogammaglobulinemia and recurrent infections.
CC       {ECO:0000269|PubMed:25133428}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the PI3K p85 subunit family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PIK3R1ID41717ch5q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M61906; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; U49349; AAB04140.1; -; mRNA.
DR   EMBL; AF279367; AAO15359.1; -; mRNA.
DR   EMBL; AK094785; BAG52931.1; -; mRNA.
DR   EMBL; AK223613; BAD97333.1; -; mRNA.
DR   EMBL; AC016564; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104120; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471137; EAW51312.1; -; Genomic_DNA.
DR   EMBL; CH471137; EAW51313.1; -; Genomic_DNA.
DR   EMBL; BC030815; AAH30815.1; -; mRNA.
DR   EMBL; BC094795; AAH94795.1; -; mRNA.
DR   CCDS; CCDS3993.1; -. [P27986-1]
DR   CCDS; CCDS3994.1; -. [P27986-3]
DR   CCDS; CCDS3995.1; -. [P27986-2]
DR   CCDS; CCDS56374.1; -. [P27986-5]
DR   PIR; A38748; A38748.
DR   RefSeq; NP_001229395.1; NM_001242466.1. [P27986-5]
DR   RefSeq; NP_852556.2; NM_181504.3. [P27986-2]
DR   RefSeq; NP_852664.1; NM_181523.2. [P27986-1]
DR   RefSeq; NP_852665.1; NM_181524.1. [P27986-3]
DR   RefSeq; XP_005248599.1; XM_005248542.3. [P27986-1]
DR   RefSeq; XP_016865074.1; XM_017009585.1. [P27986-1]
DR   UniGene; Hs.132225; -.
DR   UniGene; Hs.604502; -.
DR   UniGene; Hs.734132; -.
DR   PDB; 1A0N; NMR; -; A=91-104.
DR   PDB; 1AZG; NMR; -; A=91-104.
DR   PDB; 1H9O; X-ray; 1.79 A; A=617-724.
DR   PDB; 1PBW; X-ray; 2.00 A; A/B=105-319.
DR   PDB; 1PHT; X-ray; 2.00 A; A=1-85.
DR   PDB; 1PIC; NMR; -; A=617-724.
DR   PDB; 1PKS; NMR; -; A=1-79.
DR   PDB; 1PKT; NMR; -; A=1-79.
DR   PDB; 2IUG; X-ray; 1.89 A; A=321-440.
DR   PDB; 2IUH; X-ray; 2.00 A; A=321-440.
DR   PDB; 2IUI; X-ray; 2.40 A; A/B=321-440.
DR   PDB; 2RD0; X-ray; 3.05 A; B=322-600.
DR   PDB; 2V1Y; X-ray; 2.40 A; B=431-600.
DR   PDB; 3HHM; X-ray; 2.80 A; B=322-694.
DR   PDB; 3HIZ; X-ray; 3.30 A; B=322-694.
DR   PDB; 3I5R; X-ray; 1.70 A; A=1-83.
DR   PDB; 3I5S; X-ray; 3.00 A; A/B/C/D=1-83.
DR   PDB; 4A55; X-ray; 3.50 A; B=322-600.
DR   PDB; 4JPS; X-ray; 2.20 A; B=307-593.
DR   PDB; 4L1B; X-ray; 2.59 A; B=318-615.
DR   PDB; 4L23; X-ray; 2.50 A; B=318-615.
DR   PDB; 4L2Y; X-ray; 2.80 A; B=318-615.
DR   PDB; 4OVU; X-ray; 2.96 A; B=322-600.
DR   PDB; 4OVV; X-ray; 3.50 A; B=322-600.
DR   PDB; 4WAF; X-ray; 2.39 A; B=306-617.
DR   PDB; 4YKN; X-ray; 2.90 A; A=318-615.
DR   PDB; 4ZOP; X-ray; 2.62 A; B=307-590.
DR   PDB; 5AUL; X-ray; 1.10 A; A=614-720.
DR   PDB; 5FI4; X-ray; 2.50 A; B=306-617.
DR   PDB; 5GJI; X-ray; 0.90 A; A=325-430.
DR   PDB; 5ITD; X-ray; 3.02 A; B=307-617.
DR   PDB; 5M6U; X-ray; 2.85 A; B=1-724.
DR   PDB; 5SW8; X-ray; 3.30 A; B=322-600.
DR   PDB; 5SWG; X-ray; 3.11 A; B=322-600.
DR   PDB; 5SWO; X-ray; 3.50 A; B=322-600.
DR   PDB; 5SWP; X-ray; 3.41 A; B=322-600.
DR   PDB; 5SWR; X-ray; 3.31 A; B=322-600.
DR   PDB; 5SWT; X-ray; 3.49 A; B=322-600.
DR   PDB; 5SX8; X-ray; 3.47 A; B=322-600.
DR   PDB; 5SX9; X-ray; 3.52 A; B=322-600.
DR   PDB; 5SXA; X-ray; 3.35 A; B=322-600.
DR   PDB; 5SXB; X-ray; 3.30 A; B=322-600.
DR   PDB; 5SXC; X-ray; 3.55 A; B=322-600.
DR   PDB; 5SXD; X-ray; 3.50 A; B=322-600.
DR   PDB; 5SXE; X-ray; 3.51 A; B=322-600.
DR   PDB; 5SXF; X-ray; 3.46 A; B=322-600.
DR   PDB; 5SXI; X-ray; 3.40 A; B=322-600.
DR   PDB; 5SXJ; X-ray; 3.42 A; B=322-600.
DR   PDB; 5SXK; X-ray; 3.55 A; B=322-600.
DR   PDB; 5UBT; X-ray; 2.83 A; B=432-599.
DR   PDBsum; 1A0N; -.
DR   PDBsum; 1AZG; -.
DR   PDBsum; 1H9O; -.
DR   PDBsum; 1PBW; -.
DR   PDBsum; 1PHT; -.
DR   PDBsum; 1PIC; -.
DR   PDBsum; 1PKS; -.
DR   PDBsum; 1PKT; -.
DR   PDBsum; 2IUG; -.
DR   PDBsum; 2IUH; -.
DR   PDBsum; 2IUI; -.
DR   PDBsum; 2RD0; -.
DR   PDBsum; 2V1Y; -.
DR   PDBsum; 3HHM; -.
DR   PDBsum; 3HIZ; -.
DR   PDBsum; 3I5R; -.
DR   PDBsum; 3I5S; -.
DR   PDBsum; 4A55; -.
DR   PDBsum; 4JPS; -.
DR   PDBsum; 4L1B; -.
DR   PDBsum; 4L23; -.
DR   PDBsum; 4L2Y; -.
DR   PDBsum; 4OVU; -.
DR   PDBsum; 4OVV; -.
DR   PDBsum; 4WAF; -.
DR   PDBsum; 4YKN; -.
DR   PDBsum; 4ZOP; -.
DR   PDBsum; 5AUL; -.
DR   PDBsum; 5FI4; -.
DR   PDBsum; 5GJI; -.
DR   PDBsum; 5ITD; -.
DR   PDBsum; 5M6U; -.
DR   PDBsum; 5SW8; -.
DR   PDBsum; 5SWG; -.
DR   PDBsum; 5SWO; -.
DR   PDBsum; 5SWP; -.
DR   PDBsum; 5SWR; -.
DR   PDBsum; 5SWT; -.
DR   PDBsum; 5SX8; -.
DR   PDBsum; 5SX9; -.
DR   PDBsum; 5SXA; -.
DR   PDBsum; 5SXB; -.
DR   PDBsum; 5SXC; -.
DR   PDBsum; 5SXD; -.
DR   PDBsum; 5SXE; -.
DR   PDBsum; 5SXF; -.
DR   PDBsum; 5SXI; -.
DR   PDBsum; 5SXJ; -.
DR   PDBsum; 5SXK; -.
DR   PDBsum; 5UBT; -.
DR   ProteinModelPortal; P27986; -.
DR   SMR; P27986; -.
DR   BioGrid; 111313; 160.
DR   DIP; DIP-119N; -.
DR   IntAct; P27986; 229.
DR   MINT; MINT-93751; -.
DR   STRING; 9606.ENSP00000274335; -.
DR   BindingDB; P27986; -.
DR   ChEMBL; CHEMBL2506; -.
DR   DrugBank; DB01064; Isoprenaline.
DR   DrugBank; DB05210; SF1126.
DR   iPTMnet; P27986; -.
DR   PhosphoSitePlus; P27986; -.
DR   BioMuta; PIK3R1; -.
DR   DMDM; 118572681; -.
DR   EPD; P27986; -.
DR   MaxQB; P27986; -.
DR   PaxDb; P27986; -.
DR   PeptideAtlas; P27986; -.
DR   PRIDE; P27986; -.
DR   DNASU; 5295; -.
DR   Ensembl; ENST00000320694; ENSP00000323512; ENSG00000145675. [P27986-3]
DR   Ensembl; ENST00000336483; ENSP00000338554; ENSG00000145675. [P27986-2]
DR   Ensembl; ENST00000521381; ENSP00000428056; ENSG00000145675. [P27986-1]
DR   Ensembl; ENST00000521657; ENSP00000429277; ENSG00000145675. [P27986-1]
DR   Ensembl; ENST00000523872; ENSP00000430098; ENSG00000145675. [P27986-5]
DR   GeneID; 5295; -.
DR   KEGG; hsa:5295; -.
DR   UCSC; uc003jva.4; human. [P27986-1]
DR   CTD; 5295; -.
DR   DisGeNET; 5295; -.
DR   GeneCards; PIK3R1; -.
DR   HGNC; HGNC:8979; PIK3R1.
DR   HPA; CAB004268; -.
DR   HPA; HPA001216; -.
DR   MalaCards; PIK3R1; -.
DR   MIM; 171833; gene.
DR   MIM; 269880; phenotype.
DR   MIM; 615214; phenotype.
DR   MIM; 616005; phenotype.
DR   neXtProt; NX_P27986; -.
DR   OpenTargets; ENSG00000145675; -.
DR   Orphanet; 397596; Activated PIK3-delta syndrome.
DR   Orphanet; 33110; Autosomal agammaglobulinemia.
DR   Orphanet; 3163; SHORT syndrome.
DR   PharmGKB; PA33312; -.
DR   eggNOG; KOG4637; Eukaryota.
DR   eggNOG; ENOG410XP6R; LUCA.
DR   GeneTree; ENSGT00390000010431; -.
DR   HOGENOM; HOG000008438; -.
DR   HOVERGEN; HBG082100; -.
DR   InParanoid; P27986; -.
DR   KO; K02649; -.
DR   OMA; PQYWLTL; -.
DR   OrthoDB; EOG091G0C3Z; -.
DR   PhylomeDB; P27986; -.
DR   TreeFam; TF102033; -.
DR   BioCyc; MetaCyc:ENSG00000145675-MONOMER; -.
DR   BRENDA; 2.7.1.153; 2681.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1266695; Interleukin-7 signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-180292; GAB1 signalosome.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-198203; PI3K/AKT activation.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-210993; Tie2 Signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-373753; Nephrin interactions.
DR   Reactome; R-HSA-388841; Costimulation by the CD28 family.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-430116; GP1b-IX-V activation signalling.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-512988; Interleukin-3, 5 and GM-CSF signaling.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-HSA-5654695; PI-3K cascade:FGFR2.
DR   Reactome; R-HSA-5654710; PI-3K cascade:FGFR3.
DR   Reactome; R-HSA-5654720; PI-3K cascade:FGFR4.
DR   Reactome; R-HSA-5655253; Signaling by FGFR2 in disease.
DR   Reactome; R-HSA-5655291; Signaling by FGFR4 in disease.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8851907; MET activates PI3K/AKT signaling.
DR   Reactome; R-HSA-8853334; Signaling by FGFR3 fusions in cancer.
DR   Reactome; R-HSA-8853338; Signaling by FGFR3 point mutants in cancer.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; P27986; -.
DR   SIGNOR; P27986; -.
DR   ChiTaRS; PIK3R1; human.
DR   EvolutionaryTrace; P27986; -.
DR   GeneWiki; PIK3R1; -.
DR   GenomeRNAi; 5295; -.
DR   PRO; PR:P27986; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000145675; -.
DR   CleanEx; HS_PIK3R1; -.
DR   ExpressionAtlas; P27986; baseline and differential.
DR   Genevisible; P27986; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005801; C:cis-Golgi network; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:1990578; C:perinuclear endoplasmic reticulum membrane; IEA:Ensembl.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; ISS:BHF-UCL.
DR   GO; GO:0005943; C:phosphatidylinositol 3-kinase complex, class IA; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; TAS:Reactome.
DR   GO; GO:0046935; F:1-phosphatidylinositol-3-kinase regulator activity; IBA:GO_Central.
DR   GO; GO:0043125; F:ErbB-3 class receptor binding; IDA:UniProtKB.
DR   GO; GO:0043559; F:insulin binding; IDA:UniProtKB.
DR   GO; GO:0005158; F:insulin receptor binding; IPI:UniProtKB.
DR   GO; GO:0043560; F:insulin receptor substrate binding; ISS:BHF-UCL.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0005168; F:neurotrophin TRKA receptor binding; IPI:UniProtKB.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; ISS:BHF-UCL.
DR   GO; GO:0035014; F:phosphatidylinositol 3-kinase regulator activity; ISS:UniProtKB.
DR   GO; GO:0036312; F:phosphatidylinositol 3-kinase regulatory subunit binding; IEA:Ensembl.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0001784; F:phosphotyrosine binding; IPI:CAFA.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0005068; F:transmembrane receptor protein tyrosine kinase adaptor activity; ISS:BHF-UCL.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0030183; P:B cell differentiation; IEA:Ensembl.
DR   GO; GO:0001678; P:cellular glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:UniProtKB.
DR   GO; GO:0034644; P:cellular response to UV; IEA:Ensembl.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0060396; P:growth hormone receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0051531; P:NFAT protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046854; P:phosphatidylinositol phosphorylation; ISS:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:1900103; P:positive regulation of endoplasmic reticulum unfolded protein response; IMP:UniProtKB.
DR   GO; GO:0090004; P:positive regulation of establishment of protein localization to plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; ISS:BHF-UCL.
DR   GO; GO:2001275; P:positive regulation of glucose import in response to insulin stimulus; ISS:AgBase.
DR   GO; GO:0033120; P:positive regulation of RNA splicing; IMP:UniProtKB.
DR   GO; GO:0042993; P:positive regulation of transcription factor import into nucleus; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0050821; P:protein stabilization; IDA:UniProtKB.
DR   GO; GO:0046626; P:regulation of insulin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043551; P:regulation of phosphatidylinositol 3-kinase activity; ISS:BHF-UCL.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; IEA:Ensembl.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:UniProtKB.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR032498; PI3K_P85_iSH2.
DR   InterPro; IPR001720; PI3kinase_P85.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   InterPro; IPR000198; RhoGAP_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR10155; PTHR10155; 1.
DR   Pfam; PF16454; PI3K_P85_iSH2; 1.
DR   Pfam; PF00620; RhoGAP; 1.
DR   Pfam; PF00017; SH2; 2.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00324; RhoGAP; 1.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF48350; SSF48350; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   PROSITE; PS50238; RHOGAP; 1.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Disease mutation; Dwarfism; Host-virus interaction; Phosphoprotein;
KW   Polymorphism; Protein transport; Reference proteome; Repeat;
KW   SH2 domain; SH3 domain; Stress response; Transport; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    724       Phosphatidylinositol 3-kinase regulatory
FT                                subunit alpha.
FT                                /FTId=PRO_0000080758.
FT   DOMAIN        3     79       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      113    301       Rho-GAP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00172}.
FT   DOMAIN      333    428       SH2 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      624    718       SH2 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES     154    154       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     279    279       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     467    467       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P26450}.
FT   MOD_RES     580    580       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     608    608       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P23727}.
FT   VAR_SEQ       1    363       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045903.
FT   VAR_SEQ       1    300       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_021841.
FT   VAR_SEQ       1    270       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8628286,
FT                                ECO:0000303|Ref.5}.
FT                                /FTId=VSP_021842.
FT   VAR_SEQ     271    304       MLFRFSAASSDNTENLIKVIEILISTEWNERQPA -> MYN
FT                                TVWNMEDLDLEYAKTDINCGTDLMFYIEMDP (in
FT                                isoform 2). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8628286,
FT                                ECO:0000303|Ref.5}.
FT                                /FTId=VSP_021843.
FT   VAR_SEQ     301    306       RQPAPA -> MHNLQT (in isoform 3).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_021844.
FT   VAR_SEQ     605    605       D -> ENFLSCLPS (in isoform 4).
FT                                {ECO:0000303|PubMed:8628286}.
FT                                /FTId=VSP_021845.
FT   VARIANT     326    326       M -> I (does not affect insulin-
FT                                stimulated lipid kinase activity;
FT                                dbSNP:rs3730089).
FT                                {ECO:0000269|PubMed:10768093,
FT                                ECO:0000269|PubMed:9032108,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_010023.
FT   VARIANT     409    409       R -> Q (in a patient with severe insulin
FT                                resistance; lower insulin-stimulated
FT                                lipid kinase activity compared with wild-
FT                                type; dbSNP:rs748784250).
FT                                {ECO:0000269|PubMed:10768093}.
FT                                /FTId=VAR_010024.
FT   VARIANT     451    451       E -> K (in dbSNP:rs17852841).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_029562.
FT   VARIANT     489    489       E -> K (in SHORTS; there is 70 to 90%
FT                                reduction in the effect of insulin on
FT                                AKT1 activation, glycogen synthesis and
FT                                glucose uptake, indicating severe insulin
FT                                resistance for both proximal and distal
FT                                PI3K-dependent signaling;
FT                                dbSNP:rs397514047).
FT                                {ECO:0000269|PubMed:23810378}.
FT                                /FTId=VAR_070221.
FT   VARIANT     539    539       Missing (in SHORTS; there is 70 to 90%
FT                                reduction in the effect of insulin on
FT                                AKT1 activation, glycogen synthesis and
FT                                glucose uptake, indicating severe insulin
FT                                resistance for both proximal and distal
FT                                PI3K-dependent signaling).
FT                                {ECO:0000269|PubMed:23810378}.
FT                                /FTId=VAR_070222.
FT   VARIANT     649    649       R -> W (in SHORTS; impairs interaction
FT                                between PIK3R1 and IRS1 and reduces AKT1-
FT                                mediated insulin signaling;
FT                                dbSNP:rs397515453).
FT                                {ECO:0000269|PubMed:23810379,
FT                                ECO:0000269|PubMed:23810382}.
FT                                /FTId=VAR_070223.
FT   CONFLICT    330    330       D -> N (in Ref. 1; M61906).
FT                                {ECO:0000305}.
FT   CONFLICT    460    460       S -> G (in Ref. 4; BAG52931).
FT                                {ECO:0000305}.
FT   STRAND        4     10       {ECO:0000244|PDB:3I5R}.
FT   STRAND       29     33       {ECO:0000244|PDB:3I5R}.
FT   HELIX        34     40       {ECO:0000244|PDB:3I5R}.
FT   TURN         43     45       {ECO:0000244|PDB:3I5R}.
FT   HELIX        46     48       {ECO:0000244|PDB:3I5R}.
FT   HELIX        50     53       {ECO:0000244|PDB:3I5R}.
FT   STRAND       55     60       {ECO:0000244|PDB:3I5R}.
FT   TURN         61     64       {ECO:0000244|PDB:3I5R}.
FT   STRAND       65     70       {ECO:0000244|PDB:3I5R}.
FT   HELIX        71     73       {ECO:0000244|PDB:3I5R}.
FT   STRAND       74     81       {ECO:0000244|PDB:3I5R}.
FT   TURN        100    102       {ECO:0000244|PDB:1AZG}.
FT   HELIX       118    121       {ECO:0000244|PDB:1PBW}.
FT   HELIX       130    143       {ECO:0000244|PDB:1PBW}.
FT   TURN        147    150       {ECO:0000244|PDB:1PBW}.
FT   HELIX       160    164       {ECO:0000244|PDB:1PBW}.
FT   STRAND      167    170       {ECO:0000244|PDB:1PBW}.
FT   HELIX       174    176       {ECO:0000244|PDB:1PBW}.
FT   HELIX       179    191       {ECO:0000244|PDB:1PBW}.
FT   STRAND      193    195       {ECO:0000244|PDB:1PBW}.
FT   HELIX       200    209       {ECO:0000244|PDB:1PBW}.
FT   HELIX       210    212       {ECO:0000244|PDB:1PBW}.
FT   HELIX       216    227       {ECO:0000244|PDB:1PBW}.
FT   HELIX       234    252       {ECO:0000244|PDB:1PBW}.
FT   HELIX       254    257       {ECO:0000244|PDB:1PBW}.
FT   HELIX       261    273       {ECO:0000244|PDB:1PBW}.
FT   HELIX       280    295       {ECO:0000244|PDB:1PBW}.
FT   HELIX       323    325       {ECO:0000244|PDB:4L23}.
FT   HELIX       328    330       {ECO:0000244|PDB:5GJI}.
FT   STRAND      334    337       {ECO:0000244|PDB:4WAF}.
FT   HELIX       340    347       {ECO:0000244|PDB:5GJI}.
FT   STRAND      354    359       {ECO:0000244|PDB:5GJI}.
FT   HELIX       363    365       {ECO:0000244|PDB:2IUG}.
FT   STRAND      368    374       {ECO:0000244|PDB:5GJI}.
FT   STRAND      377    386       {ECO:0000244|PDB:5GJI}.
FT   STRAND      389    395       {ECO:0000244|PDB:5GJI}.
FT   STRAND      398    400       {ECO:0000244|PDB:5GJI}.
FT   HELIX       401    409       {ECO:0000244|PDB:5GJI}.
FT   HELIX       413    415       {ECO:0000244|PDB:5GJI}.
FT   HELIX       418    420       {ECO:0000244|PDB:5GJI}.
FT   TURN        430    432       {ECO:0000244|PDB:2IUG}.
FT   HELIX       433    436       {ECO:0000244|PDB:4WAF}.
FT   HELIX       442    515       {ECO:0000244|PDB:4JPS}.
FT   HELIX       518    587       {ECO:0000244|PDB:4JPS}.
FT   HELIX       591    598       {ECO:0000244|PDB:2V1Y}.
FT   HELIX       617    619       {ECO:0000244|PDB:5AUL}.
FT   HELIX       621    623       {ECO:0000244|PDB:5AUL}.
FT   STRAND      625    629       {ECO:0000244|PDB:1PIC}.
FT   HELIX       631    638       {ECO:0000244|PDB:5AUL}.
FT   STRAND      645    650       {ECO:0000244|PDB:5AUL}.
FT   STRAND      652    655       {ECO:0000244|PDB:1PIC}.
FT   STRAND      657    663       {ECO:0000244|PDB:5AUL}.
FT   STRAND      666    675       {ECO:0000244|PDB:5AUL}.
FT   STRAND      678    682       {ECO:0000244|PDB:5AUL}.
FT   STRAND      688    690       {ECO:0000244|PDB:5AUL}.
FT   HELIX       691    698       {ECO:0000244|PDB:5AUL}.
FT   HELIX       703    705       {ECO:0000244|PDB:5AUL}.
FT   TURN        708    710       {ECO:0000244|PDB:1PIC}.
FT   STRAND      716    719       {ECO:0000244|PDB:1PIC}.
SQ   SEQUENCE   724 AA;  83598 MW;  B9DAD8416C33140F CRC64;
     MSAEGYQYRA LYDYKKEREE DIDLHLGDIL TVNKGSLVAL GFSDGQEARP EEIGWLNGYN
     ETTGERGDFP GTYVEYIGRK KISPPTPKPR PPRPLPVAPG SSKTEADVEQ QALTLPDLAE
     QFAPPDIAPP LLIKLVEAIE KKGLECSTLY RTQSSSNLAE LRQLLDCDTP SVDLEMIDVH
     VLADAFKRYL LDLPNPVIPA AVYSEMISLA PEVQSSEEYI QLLKKLIRSP SIPHQYWLTL
     QYLLKHFFKL SQTSSKNLLN ARVLSEIFSP MLFRFSAASS DNTENLIKVI EILISTEWNE
     RQPAPALPPK PPKPTTVANN GMNNNMSLQD AEWYWGDISR EEVNEKLRDT ADGTFLVRDA
     STKMHGDYTL TLRKGGNNKL IKIFHRDGKY GFSDPLTFSS VVELINHYRN ESLAQYNPKL
     DVKLLYPVSK YQQDQVVKED NIEAVGKKLH EYNTQFQEKS REYDRLYEEY TRTSQEIQMK
     RTAIEAFNET IKIFEEQCQT QERYSKEYIE KFKREGNEKE IQRIMHNYDK LKSRISEIID
     SRRRLEEDLK KQAAEYREID KRMNSIKPDL IQLRKTRDQY LMWLTQKGVR QKKLNEWLGN
     ENTEDQYSLV EDDEDLPHHD EKTWNVGSSN RNKAENLLRG KRDGTFLVRE SSKQGCYACS
     VVVDGEVKHC VINKTATGYG FAEPYNLYSS LKELVLHYQH TSLVQHNDSL NVTLAYPVYA
     QQRR
//
